PMID: 6112563Jun 6, 1981Paper

Induction of high kidney graft survival rate by multiple transfusion

Lancet
G OpelzP Terasaki

Abstract

In 33 centres that adopted a policy of liberal preoperative blood transfusion 174 recipients of cadaver donor transplants were followed up. Those who received no pretransplant transfusions had a 23% 1-year graft survival rate whereas those who had greater than 10 transfusions had an 87% survival rate (p less than 0.000001). 3% of those transfused acquired highly reactive cytotoxic antibodies and greater than 70% had no antibodies, so transfusions do not exert their beneficial effect by excluding strong immune responders. Since transplant survival rates improved with the number of transfusions, they probably produce their beneficial effect by inducing a state of unresponsiveness. Multiple transfusion seems a simple and effective way of improving kidney transplant survival rates. Moreover, the immunosuppressive effect is specific in that it does not alter the immune response to infectious agents.

Citations

Jan 1, 1986·Journal of Cancer Research and Clinical Oncology·R L MarquetJ Jeekel
Dec 13, 2005·Surgery Today·Tadamichi HiranoJiro Fujimoto
Jun 25, 2002·The Annals of Thoracic Surgery·Stephen M LangleyDavid F Weeden
Dec 9, 1982·The New England Journal of Medicine·W SzmunessA Kellner
May 5, 1983·The New England Journal of Medicine·Y VanrenterghemP Michielsen
Jun 1, 1994·Transfusion Medicine·J PinkB Wylie
Sep 1, 1981·Archives of Disease in Childhood·S RigdenC Chantler
Oct 23, 1982·British Medical Journal·E SavdieA G Sheil
Oct 1, 1985·The Australian and New Zealand Journal of Surgery·R T JudsonA J D'Apice
Oct 1, 1987·European Journal of Cancer & Clinical Oncology·R S Foster
May 16, 2006·Thoracic Surgery Clinics·Ryan C Fields, Bryan F Meyers
Jan 1, 1987·The British Journal of Surgery·D M Francis, R T Judson
Mar 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F LiewaldW Mempel
Mar 1, 1987·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J M WellerF K Port
Jan 28, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Giorgio BoganiFrancesco Raspagliesi
Mar 1, 1996·Journal of Surgical Oncology·M J Chmell, H S Schwartz
Mar 21, 1998·The British Journal of Surgery·M JohnsonA V Wu
May 28, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·J LeiJ F Markmann
Jan 1, 1991·The British Journal of Surgery·J G WilliamsS M Goldberg
Apr 1, 1988·The British Journal of Surgery·S K SinghJ Jeekel
Mar 23, 1999·The American Journal of Gastroenterology·M TachibanaN Nagasue
Jan 1, 1982·Critical Reviews in Clinical Laboratory Sciences·C R Valeri
Jan 1, 1996·Anesthesia and Analgesia·D F LandersI J Fox
Aug 15, 2017·Current Opinion in Hematology·Lyla A Youssef, Steven L Spitalnik
Jun 17, 2015·Langenbeck's Archives of Surgery·Christian MorathChristian Kleist
Mar 22, 2002·Pediatric Transplantation·Peter H Lapchak, David M Briscoe
Jul 1, 1997·Clinical Orthopaedics and Related Research·M H Tan, H J Mankin
Jan 1, 1995·Immunological Investigations·M S Mincheff, H T Meryman
Jan 1, 1986·Vox Sanguinis·H Cottier, A Hässig
Sep 1, 1983·Kidney International·E G Neilson, B Zakheim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.